AFP and neoplasm: Because early-stage tumor diagnosis improves options for potentially curative therapy and thereby improves overall survival (12), AASLD guidelines recommend surveillance in CLD patients at risk for HCC (8, 13) with liver ultrasound (US) and serum alpha-fetoprotein (AFP) test conducted every 6 months (14).